Ahmed M. Bayoumi

MD, MSc

Scientist, Li Ka Shing Knowledge Institute

Biography

Dr. Ahmed Bayoumi is a Scientist at the Centre for Urban Health Solutions at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, a general internist and Human Immunodeficiency Virus (HIV) physician at St. Michael’s Hospital. He holds the Fondation Baxter & Alma Ricard Chair in Inner City Health at St. Michael’s and the University of Toronto. He is a Professor in the Department of Medicine and in the Institute of Health Policy, Management and Evaluation at the University of Toronto.

His research interests include economic evaluation, decision analysis, and quality of life assessment for HIV-related health interventions, and studies of the access to the delivery of health services, particularly to people living with HIV, injection drug users, and other marginalized populations. His work has included cost-effectiveness analyses of screening strategies for HIV, drug treatments for HIV and related conditions, and supervised injection sites for injection drug users. He also studies how to incorporate equity concerns into resource allocation decisions in a manner that is defensible, transparent, and principled. He is an Adjunct Scientist at the Institute for Clinical Evaluative Sciences. He is currently President of the Society for Medical Decision Making and is a member of the Canadian Drug Expert Committee. He is a past Director of Clinical Epidemiology and Health Care Research in the Institute of Health Policy, Management and Evaluation at the University of Toronto.

Please note: Dr. Bayoumi is not taking any summer students in 2018.

Recent Publications

  1. Abdel Hafez, SMN, Rifaai, RA, Bayoumi, AMA. Impact of renal ischemia/reperfusion injury on the rat Kupffer cell as a remote cell: A biochemical, histological, immunohistochemical, and electron microscopic study. Acta Histochem. 2019; :. doi: 10.1016/j.acthis.2019.04.008. PubMed PMID:31078256 .
  2. Younger, J, Raboud, J, Szadkowski, L, Harrigan, R, Walmsley, S, Bayoumi, AM et al.. Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP. Antivir. Ther. (Lond.). 2019; :. doi: 10.3851/IMP3302. PubMed PMID:30873953 .
  3. Grewal, R, Allen, VG, Bayoumi, AM, Gardner, SL, Kaul, R, Mazzulli, T et al.. Brief Report: Syphilis Coinfection Is Not Associated With an Increased Risk of Virologic Failure Among HIV-Positive Men Who Have Sex With Men on Antiretroviral Therapy. J. Acquir. Immune Defic. Syndr. 2019;80 (5):585-589. doi: 10.1097/QAI.0000000000001962. PubMed PMID:30730358 .
  4. Yoong, D, Bayoumi, AM, Robinson, L, Rachlis, B, Antoniou, T. Public prescription drug plan coverage for antiretrovirals and the potential cost to people living with HIV in Canada: a descriptive study. CMAJ Open. ;6 (4):E551-E560. doi: 10.9778/cmajo.20180058. PubMed PMID:30482757 PubMed Central PMC6276936.
  5. Ewees, MG, Messiha, BAS, Abo-Saif, AA, Bayoumi, AMA, Abdel-Bakky, MS. Interference With Coagulation Cascade as a Novel Approach to Counteract Cisplatin-Induced Acute Tubular Necrosis; an Experimental Study in Rats. Front Pharmacol. 2018;9 :1155. doi: 10.3389/fphar.2018.01155. PubMed PMID:30364273 PubMed Central PMC6193076.
  6. Barnett, C, Bril, V, Bayoumi, AM. EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravis. Eur. J. Neurol. 2019;26 (3):452-459. doi: 10.1111/ene.13836. PubMed PMID:30315714 .
  7. Watson, TM, Bayoumi, AM, Hopkins, S, Wright, A, Naraine, R, Khorasheh, T et al.. Creating and sustaining cooperative relationships between supervised injection services and police: A qualitative interview study of international stakeholders. Int. J. Drug Policy. 2018;61 :1-6. doi: 10.1016/j.drugpo.2018.08.001. PubMed PMID:30290363 .
  8. Shankardass, K, O'Campo, P, Muntaner, C, Bayoumi, AM, Kokkinen, L. Ideas for Extending the Approach to Evaluating Health in All Policies in South Australia Comment on "Developing a Framework for a Program Theory-Based Approach to Evaluating Policy Processes and Outcomes: Health in All Policies in South Australia". Int J Health Policy Manag. 2018;7 (8):755-757. doi: 10.15171/ijhpm.2018.25. PubMed PMID:30078296 PubMed Central PMC6077279.
  9. Ewees, MG, Messiha, BAS, Abdel-Bakky, MS, Bayoumi, AMA, Abo-Saif, AA. Tempol, a superoxide dismutase mimetic agent, reduces cisplatin-induced nephrotoxicity in rats. Drug Chem Toxicol. 2018; :1-8. doi: 10.1080/01480545.2018.1485688. PubMed PMID:30067109 .
  10. Isaranuwatchai, W, Bayoumi, AM, Renahy, E, Cheff, R, O'Campo, P. Using decision methods to examine the potential impact of intersectoral action programs. BMC Res Notes. 2018;11 (1):506. doi: 10.1186/s13104-018-3609-x. PubMed PMID:30053829 PubMed Central PMC6062875.
Search PubMed

Affiliations & Other Activities

  • Scientist, Centre for Urban Health Solutions, St. Michael’s Hospital
  • Professor, Department of Medicine, University of Toronto
  • Professor, Institute of Health Policy, Management and Evaluation, University of Toronto
X